Peptide Therapeutics intermediate
Milestone 018: Oligopeptide Research Reference
2023: SELECT trial shows semaglutide reduces cardiovascular events by 20% in obesity. This peptide or oligopeptide is studied for its biological activity, st...
By Encyclopeptide Editorial | 1 min read
milestone-018 peptide research
Overview
2023: SELECT trial shows semaglutide reduces cardiovascular events by 20% in obesity.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Milestone 018” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Milestone 018: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept